Revolution Medicines, Inc.
RVMD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001628171
In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 16 sales; 693 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesRVMDW
Holders of 5% or more of RVMD
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Revolution Medicines, Inc., largest stake first. The change is against the holder's previous filing.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
16 Schedule 13D and 13G filings on Revolution Medicines, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 15, 202611:23 AM ET | Janus Henderson Group PLC | 13G/A | 4.90%9.77M shares | −1.20 ppfrom 6.10%Below 5% | Mar 31, 2026 | SEC |
| Mar 27, 202611:38 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20264:19 PM ET | Baker Bros. Advisors LPand 3 others | 13G/A | 4.90%9.46M shares | −0.10 ppfrom 5.00%Below 5% | Dec 31, 2025 | SEC |
| Feb 10, 202611:19 AM ET | Wellington Management Group LLPand 2 others | 13G/A | 3.60%6.99M shares | −1.90 ppfrom 5.50%Below 5% | Dec 31, 2025 | SEC |
| Feb 9, 20268:53 AM ET | Farallon Capital Partners, L.P.and 30 others | 13G/A | 7.50%14.6M shares | −0.40 ppfrom 7.90% | Dec 31, 2025 | SEC |
| Nov 14, 202512:39 PM ET | Janus Henderson Group PLC | 13G/A | 6.10%11.4M shares | +0.40 ppfrom 5.70% | Sep 30, 2025 | SEC |
| Nov 5, 202511:44 AM ET | FMR LLCand 1 other | 13G | 5.00%9.40M shares | New | Sep 30, 2025 | SEC |
| Aug 14, 20254:26 PM ET | Baker Bros. Advisors LPand 3 others | 13G | 5.00%9.36M shares | New | Jun 30, 2025 | SEC |
| Aug 14, 202511:42 AM ET | Janus Henderson Group PLC | 13G/A | 5.70%10.6M shares | +0.20 ppfrom 5.50% | Jun 30, 2025 | SEC |
| Aug 12, 202510:34 AM ET | Wellington Management Group LLPand 3 others | 13G/A | 5.50%10.3M shares | – | Jun 30, 2025 | SEC |
| Jul 17, 20257:54 PM ET | BlackRock, Inc. | 13G/A | 4.50%8.40M shares | –Below 5% | Jun 30, 2025 | SEC |
| May 15, 20259:24 AM ET | Farallon Capital Partners, L.P.and 29 others | 13G/A | 7.90%13.3M shares | +1.00 ppfrom 6.90% | Dec 31, 2024 | SEC |
| May 15, 20259:23 AM ET | Farallon Capital Partners, L.P.and 28 others | 13G/A | 6.90%11.3M shares | +1.80 ppfrom 5.10% | Sep 30, 2024 | SEC |
| May 15, 20259:22 AM ET | Farallon Capital Partners, L.P.and 28 others | 13G | 5.10%8.38M shares | New | Apr 12, 2024 | SEC |
| May 14, 202512:29 PM ET | Janus Henderson Group PLC | 13G/A | 5.50%10.2M shares | +0.30 ppfrom 5.20% | Mar 31, 2025 | SEC |
| Feb 14, 202511:25 AM ET | Janus Henderson Group PLC | 13G | 5.20%9.48M shares | New | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
2 notices from officers, directors and other affiliates planning to sell Revolution Medicines, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 20264:17 PM ET | Anthony ManciniOfficer | 9.36K | $1.87M | Sep 25, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Sep 24, 20264:42 PM ET | Anthony ManciniOfficer | 587 | $112.0K | Sep 24, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |